| Authors: |
Topp MS; University Hospital of Würzburg, Würzburg, Germany. Topp_M@ukw.de., Shah BD; Moffitt Cancer Center, Tampa, FL, USA., Jabbour E; University of Texas MD Anderson Cancer Center, Houston, TX, USA., Park JH; Memorial Sloan Kettering Cancer Center, New York, NY, USA., Shaughnessy P; Methodist Hospital, San Antonio, TX, USA., Logan AC; University of California at San Francisco, San Francisco, CA, USA., Sandhu KS; City of Hope National Medical Center, Duarte, CA, USA., Abedi M; University of California Davis, Davis, CA, USA., Bishop MR; University of Chicago, Chicago, IL, USA., DeAngelo DJ; Dana-Farber Cancer Institute, Boston, MA, USA., Yin X; Medidata, New York, NY, USA., Davi R; Medidata, New York, NY, USA., Hodby K; University Hospitals Bristol NHS Foundation Trust, Bristol, UK., Malladi R; Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK., Brugger W; Autolus Therapeutics, Munich, Germany., Shang J; Autolus Therapeutics, Rockville, MD, USA., Roddie C; University College London Cancer Institute, London, UK., Kantarjian HM; University of Texas MD Anderson Cancer Center, Houston, TX, USA. |
